

Form PTO-1449 Substitute

Applicant(s): Velayudhan Sahadevan

Filing Date: February 27, 2002, "Hormonal Implant Treatment of Breast Cancer"

U.S. Patent Documents

	<u>Ret.</u>	<u>Number</u>	Issue Date	Name(s)	Class Subclass	<u>Filing Date</u>
`	(16)	4,321,208	03/23/1982	Sahadevan, V.	552/627; 552/544	09/27/1976
	(18)	4,389,330	06/21/1983	Tice; Thomas R.	427/213.36;264/4.1	10/06/1980
	(19)	5,340,586	08/23/1994	Pike;Malcolm C.; S	424/426; 424/43	05/17/1993
	(20)	4,244,949	01/13/1981	Gupta; Gopi N.	514/178; A61K 031/56	04/06/1978
	(21)	5,340,585	08/23/1994	Pike, Malcolm C.,	424/426; 424/42	05/17/1993
	(22)	4,210,644	07/01/1980	Ewing: Larry L.; D	514/170; 514/84	02/23/1978
				= •		

Foreign Patent Documents

Initial Number 1	ssue Date	Country	Class	Subclass	Translated

Reference # and Other Prior Art

Ref. (Including Authors, Title, Date, Pertinent Pages, Etc.)

- 1. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast,
 In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S.
 and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1656-; Ref. # 110: Early
 Breast Cancer Trialists's Collaborative Group. Tamoxifen for early breast cancer: an
 - overview of the randomized trials. Lancet 1998; 352:930.
 - Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1656-; Ref.#111: Nayfield

SG, Karp JE, Ford LG, Dorr FA, Kramer FS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 1991;83:1450.

- 3. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1656-; Ref. # 112:

 Radmacher MD, Simon R. Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. J Natl Cancer Inst 2000;92:48.
- 4. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1656-; Ref. #118: Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637.
- Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1656-; Ref. # 119:

 Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189.



- 6. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1690, Table 37.2-20
- 7. Erlichman C, and Loprinzi CL, Hormonal Therapies, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 479-80, Ref # 61, Hayes DF, Vanzyl JA, Hacking A, et al, Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer, J Clin Oncol 1995; 13: 2556.
- Erlichman C, and Loprinzi CL, Hormonal Therapies, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 480.
- 9. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1691, Ref, # 113, Fisher B, Costantino JP, Wickerham DL, et.al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowl Project P-1 study. J Natl Cancer Inst 1998; 90:1371.
- 10. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S.

and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 1657-; Ref. # 113: Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371.

- 11. Winer E. P., Morrow M., Osborne C. K., and Harris J. R., Malignant Tumors of the Breast, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins,2001 page 1657-; Ref. # 114: Day R, Ganz PA, Costantino JP. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659.
- 12. Haller DG, Fox KR, Schuchter LM, Metastatic Breast Cancer; In Breast Cancer Treatment A Comprehensive Guide to Management; Fowble B, Goodman RL, Glick JH and Rosato EF (Ed), Mosby Year Book, 1991, page 413.
- Nolvadex, tamoxifen citrate, Zeneca Pharmaceuticals, Physicians Desk Reference, PDR 51,
 1997; p 2957
- 14. Erlichman C, and Loprinzi CL, Hormonal Therapies, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 479, Ref # 52, Daniel CP, Gaskell SJ, Bishop H, et al

Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma, Eur J Cancer Clin Oncol 1981; 17: p 1183.

15. Erlichman C, and Loprinzi CL, Hormonal Therapies, In Cancer, Principles and Practice of Oncology, 6th edition, Vol. 1; DeVita, Jr., Hellman S. and Rosenberg (Ed), Lippincott Williams & Wilkins, 2001 page 479.

Sahadevan V: Preparation of directly iodinated steroid hormones and related compounds, US
 Patent 4,321,208; 1982.

17. Pharmacia and Upjohn Company, Depo-Provera, Physicians Desk Reference, PDR, 51,1997, p2079.

18. Tice TR, and Lewis DH: Microencapsulation process, US Patent 4,389,330; 1983.

19. Pike M and Spicer DV: Methods and formulations for use in treating oophorectomized women, US Patent 5,340,586; 1994.

20. Gupta GN: Manufacture of long term contraceptive implant, US Patent 4,244,949; 1981.

21. Pike M and Spicer DV: Methods and formulations for use in treating benign gynecological disorders; US Patent 5,340,585; 1994.

22. Ewing LL, Desjardins C: Male contraception; US Patent 4,210,644; 1980.

23. Norplant System, Wyeth Ayerst Laboratories, Physicians Desk Reference, PDR, 51, 1997, p2868

Examiner

Date Considered